# Ollin Biosciences, Inc.
Ollin Biosciences, Inc. is a clinical-stage biotechnology company based in [Austin, Texas](https://www.edgepedia.org/austin-texas), incorporated in Delaware in 2022, that acquires and develops antibody therapies for vision-threatening eye diseases, with two bispecific antibody (antibody engineered to bind two different targets simultaneously) candidates in-licensed from Chinese biotech partners.[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) • [2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) The company launched publicly on September 17, 2025 with $100 million in financing, and in 2026 announced an oversubscribed $330 million Series B to fund global Phase 3 trials of its lead drug candidate.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) • [3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) The Series B was still open under a June 24, 2026 Form D filing.[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt)
| Fact | Detail |
|---|---|
| Legal name and base | Ollin Biosciences, Inc., Delaware corporation, Austin, Texas[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) |
| Incorporated | 2022 per SEC Form D (company site states "established in 2023")[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) • [4](https://ollin.bio/) |
| Founders | Jason Ehrlich (CEO), Jason Coloma, Travis Murdoch[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) • [2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) |
| Lead program | OLN324, a higher-potency VEGF/Ang2 bispecific antibody for wet AMD and DME, licensed from Innovent Biologics[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) |
| Financing announced | $100M (September 2025); $330M Series B announced 2026, of which $156,249,990 sold as of June 24, 2026[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) • [3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) • [1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) |
| Main backers | ARCH Venture Partners, TCGX, Mubadala Capital, Monograph Capital, plus a16z Bio+Health, Blackstone, Commodore Capital, CPP Investments, RA Capital, T. Rowe Price-advised accounts[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) |
| Status | Active, independent; Phase 3 of OLN324 planned for second half of 2026[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) |
## History and founding
The Form D filed in June 2026 records Ollin Biosciences, Inc. as a Delaware corporation with 2022 as its year of incorporation, registered with EIN 932578229 and CIK 0002141184.[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) • [5](https://www.sec.gov/Archives/edgar/data/2141184/000214118426000002/0002141184-26-000002-index.htm) The company's own website and press release state it was established in 2023; the SEC filing is the more formal record.[4](https://ollin.bio/) • [2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/)
The company emerged from stealth on September 17, 2025, announcing an initial $100 million in financing led by [ARCH Venture Partners](https://www.edgepedia.org/arch-venture-partners), Mubadala Capital, and Monograph Capital. At launch, the JADE study was already enrolling patients, so Ollin arrived publicly with a clinical-stage lead asset rather than a preclinical platform.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/)
## Founders and leadership
Jason Ehrlich, M.D., Ph.D., is chief executive officer and a co-founder. He previously worked at Roche's Genentech, where he contributed to the development of Vabysmo (faricimab), the retina drug that Ollin's lead candidate now challenges.[6](https://www.fiercebiotech.com/biotech/ollin-eyes-phase-3-after-topping-vabysmo-head-head-trial-ollins-bispecific-antibody-tops) Co-founder Jason Coloma is chief executive of Maze Therapeutics, and co-founder Travis Murdoch, M.D., is chief executive of Braveheart Bio and former chief executive of HI-Bio.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) All three are directors of the company per the June 2026 Form D.[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt)
The board at launch was chaired by Paul Berns of ARCH Venture Partners and also included Alaa Halawa of Mubadala Ventures and Fred Cohen of Monograph Capital.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) In connection with the Series B, Cariad Chester joined the board representing TCGX, and all seven names (Ehrlich as executive officer; Berns, Coloma, Chester, Cohen, Halawa, and Murdoch as directors) appear on the June 2026 filing.[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) • [1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt)
## Products and pipeline
**OLN324** is the lead candidate: a higher-potency, small-format bispecific antibody targeting VEGF and Ang2, the same two pathways targeted by Roche's Vabysmo, for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). It was discovered by and is being developed in collaboration with [Innovent Biologics](https://www.edgepedia.org/innovent-biologics), which lists it as IBI324.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/)
The JADE study, a randomized, U.S.-based proof-of-concept trial, enrolled over 150 patients with wAMD or DME before Ollin's public launch and ultimately randomized 164 patients head-to-head against faricimab.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) • [3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) According to the company, OLN324 showed meaningfully faster and greater improvements in retinal anatomy than faricimab in both diseases and numerically greater vision gains in the small Phase 1b study.[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026)
The company completed an End-of-Phase 2 meeting with the U.S. FDA and received scientific advice from the [European Medicines Agency](https://www.edgepedia.org/european-medicines-agency) on the Phase 3 program, and it plans to begin global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026.[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026)
**OLN102** is a second program, described by the company as a first-in-class TSHR/IGF-1R bispecific antibody for thyroid eye disease and [Graves' disease](https://www.edgepedia.org/graves-disease), discovered with VelaVigo and expected to enter clinical development in 2026.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) • [4](https://ollin.bio/)
## Funding, by the numbers
Ollin's documented financing totals roughly $430 million announced across two rounds. The September 2025 launch round was $100 million, led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) In 2026 the company announced an oversubscribed $330 million Series B co-led by new investor TCGX and founding investor ARCH Venture Partners, with participation from a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, CPP Investments, RA Capital Management, accounts advised by [T. Rowe Price](https://www.edgepedia.org/t-rowe-price), a sovereign wealth fund, and continued investment from Mubadala Capital and Monograph Capital.[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026)
The June 24, 2026 Form D shows the Series B in progress rather than complete: $156,249,990 of the $330,000,000 offering had been sold to 32 investors, with $173,750,010 remaining, no stated minimum, and first sale dated May 14, 2026.[1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) The gap between the announced $330 million and the recorded $156.2 million is the difference between a press announcement of a financing and the amount actually closed and reported to the SEC at filing time.[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) • [1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt)
Chief executive Ehrlich framed the Series B against a $15 billion retina market, according to the company's announcement.[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026)
## Recent developments
Ollin did not exist publicly until 2025. The milestones since then, in order: a stealth-period incorporation recorded as 2022 on later filings; public launch with $100 million in September 2025, with the JADE study already running; JADE topline results and the End-of-Phase 2 FDA meeting and EMA advice in the first half of 2026; the $330 million Series B announcement with board addition Cariad Chester in 2026; and the open Form D of June 24, 2026 recording the round at $156.2 million sold.[2](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/) • [3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) • [1](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt) The next scheduled milestone is the start of Phase 3 trials in the second half of 2026.[3](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026)
## References
1. [SEC Form D notice, Ollin Biosciences, Inc., filed 2026-06-24 (Accession 0002141184-26-000002)](https://www.sec.gov/Archives/edgar/data/2141184/0002141184-26-000002.txt)
2. [Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology (company press release, September 17, 2025)](https://ollin.bio/press-releases/ollin-biosciences-launches-with-mission-to-accelerate-best-in-class-therapies-in-ophthalmology/)
3. [Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing (Business Wire via BioSpace)](https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026)
4. [Ollin Bio company website](https://ollin.bio/)
5. [EDGAR filing index for Form D, Accession 0002141184-26-000002](https://www.sec.gov/Archives/edgar/data/2141184/000214118426000002/0002141184-26-000002-index.htm)
6. [Ollin eyes phase 3 after topping Vabysmo in head-to-head trial (Fierce Biotech)](https://www.fiercebiotech.com/biotech/ollin-eyes-phase-3-after-topping-vabysmo-head-head-trial-ollins-bispecific-antibody-tops)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Biologics and antibody developers*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026; Oct 11, 2026; Oct 15, 2026; Oct 21, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license